Pergoveris market outlook strengthens as IVF demand rises

The Pergoveris market is projected to grow through 2035 as infertility rates, IVF use and fertility treatment demand increase worldwide. Europe led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Pergoveris is used in fertility care for women with severe gonadotropin deficiency, so demand rises as more patients seek IVF and other assisted reproductive technologies. - The market outlook matters because infertility is expanding the potential patient pool and driving broader use of hormone-based fertility treatments.

What happened: - The Business Research Company released its Pergoveris Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Pergoveris market is set to evolve significantly as fertility treatments advance and awareness of reproductive health grows. - The company made a free sample report and the full market report available online.

The details: - Pergoveris is a biologic medication for women with severe gonadotropin deficiency, a condition marked by insufficient follicle-stimulating hormone (FSH) and luteinizing hormone (LH). - The drug combines recombinant FSH and LH to stimulate the ovaries and support the development of mature eggs for IVF and other assisted reproductive technologies. - Historical market growth was supported by more diagnoses of gonadotropin deficiencies, more assisted reproductive clinics, better IVF success rates, recombinant hormone technologies and higher infertility awareness. - Forecast growth is tied to stronger demand for advanced IVF protocols, precision hormone therapies, fertility tourism, patient-friendly injectable forms and investment in reproductive biotechnology. - Key trends highlighted in the report include wider use of recombinant hormone therapies, higher demand for IVF and ART procedures, adoption of injectable pen formulations, expansion of precision fertility treatments and improved management of hormone deficiencies. - Infertility is defined as the inability to conceive or carry a pregnancy to term. - The World Health Organization reported in April 2023 that about 17.5% of adults worldwide, or roughly one in six people, experience infertility. - The Human Fertilisation & Embryology Authority in the UK reported that in 2023, 52,400 patients underwent more than 77,500 IVF cycles at licensed clinics. - Egg freezing cycles in the UK rose from 4,700 in 2022 to 6,900 in 2023, accounting for 7% of all cycles. - The report says Europe led the Pergoveris market in 2025. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The geographic scope also includes Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report points to a shift from general infertility treatment toward more specialized, precision-based fertility care. - Rising use of IVF and egg freezing suggests more patients are entering the fertility-treatment pipeline earlier and in greater numbers. - Growth in fertility tourism could add cross-border demand, especially in markets with established reproductive medicine infrastructure.

What's next: - The market is expected to keep expanding as IVF adoption, precision hormone therapy and reproductive biotechnology investment increase. - The report's 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics and tables. - The Business Research Company lists contact details for expert follow-up, including Saumya Sahay at marketing@tbrc.info and its social channels on LinkedIn, Facebook and X.